Scarica l'app Stockscreener
68.92
2.76%
1.85
Precedente Chiudi:
$67.07
Aprire:
$68.52
Volume 24 ore:
1.38M
Relative Volume:
2.00
Capitalizzazione di mercato:
$3.41B
Reddito:
-
Utile/perdita netta:
$-105.43M
Rapporto P/E:
-29.73
EPS:
-2.3183
Flusso di cassa netto:
$-88.42M
1 W Prestazione:
+15.68%
1M Prestazione:
+66.84%
6M Prestazione:
+150.80%
1 anno Prestazione:
+647.51%
Intervallo 1D:
$66.80
$70.14
Intervallo di 1 settimana:
$59.35
$70.14
Portata 52W:
$8.91
$70.14
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
68.92 | 3.41B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Piper Sandler | Overweight |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Oruka Therapeutics (NASDAQ: ORKA) outlines 2026 director, auditor and pay votes - Stock Titan
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update - MarketBeat
Oruka Therapeutics price target raised to $85 from $45 at Wedbush - Yahoo Finance
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Up nearly 840% in a year, does this 'strong buy' stock have more room to run? - MSN
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares - MarketBeat
Oruka Therapeutics chief medical officer sells $462k in ORKA stock - Investing.com Canada
Oruka Therapeutics (ORKA) CMO sells 7,000 shares after exercising options - Stock Titan
ORKA (ORKA) files Rule 144 showing 21,000-share option exercise and 10b5-1 sales - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Given New $85.00 Price Target at Wedbush - MarketBeat
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com UK
Q1 Earnings Forecast for ORKA Issued By HC Wainwright - MarketBeat
Oruka Therapeutics stock hits 52-week high at 64.72 USD By Investing.com - Investing.com Australia
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - The Manila Times
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Oruka Therapeutics stock hits 52-week high at 64.72 USD - Investing.com
Does Oruka Therapeutics' (ORKA) US$1 Billion Shelf Clarify or Complicate Its Capital Strategy? - simplywall.st
ORKA Maintained by BTIG -- Price Target Raised to $78 - GuruFocus
Guggenheim Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $70.00 at HC Wainwright - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $78.00 at BTIG Research - MarketBeat
H.C. Wainwright raises Oruka Therapeutics price target to $70 - Investing.com
H.C. Wainwright raises Oruka Therapeutics price target to $70 By Investing.com - Investing.com Canada
BTIG raises Oruka Therapeutics price target on trial timeline By Investing.com - Investing.com Canada
[EFFECT] Oruka Therapeutics, Inc. SEC Filing - Stock Titan
This Startup’s Psoriasis Drug Studies Have Lifted Its Stock - Barron's
Oruka Therapeutics (NASDAQ:ORKA) Shares Down 6.4%Should You Sell? - MarketBeat
Stifel reiterates Oruka Therapeutics stock rating ahead of trial data By Investing.com - Investing.com Canada
ORKA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5% After Analyst Upgrade - Defense World
How cyclical is Oruka Therapeutics Incs revenue streamPrice Action & Community Verified Watchlist Alerts - baoquankhu1.vn
Oruka Therapeutics Is Maintained at Overweight by Barclays - Moomoo
UBS Sticks to Its Buy Rating for Oruka Therapeutics (ORKA) - The Globe and Mail
Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $78 - Moomoo
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $78.00 at Barclays - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Given New $75.00 Price Target at UBS Group - Defense World
Does Oruka Therapeutics' (ORKA) $1 Billion Shelf Plan Reframe Its Long-Term Capital Strategy? - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $75.00 at UBS Group - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Hits New 52-Week HighHere's Why - MarketBeat
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Guggenheim raises Oruka Therapeutics price target on trial outlook By Investing.com - Investing.com Canada
Secure Asset Management LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
ORKA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oruka Therapeutics may offer up to $1 billion of securities from time to timeSEC filing - marketscreener.com
Oruka Therapeutics May Offer Up To $1 Billion Of Securities From Time To TimeSEC Filing - TradingView
Oruka Therapeutics (NASDAQ: ORKA) files $1B shelf to sell equity, warrants - Stock Titan
Oruka Therapeutics Stock Surges On Bullish Breakthrough - TipRanks
Oruka Therapeutics stock hits 52-week high at 50.11 USD By Investing.com - Investing.com Australia
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.19%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):